Table 1 Clinical Characteristics (n = 42)
From: Effects of saxagliptin on early microvascular changes in patients with type 2 diabetes
| Â | Placebo | Saxagliptin | p-value |
|---|---|---|---|
HbA1c (%) | 7.10 ± 0.17 | 6.84 ± 0.15 | < 0.001 |
Glucose postprandial (mmol/L) | 10.1 ± 0.4 | 9.27 ± 0.4 | 0.001 |
Glucose fasting (mmol/L) | 7.49 ± 0.3 | 7.21 ± 0.3 | 0.097 |
Adiponectin (μg/ml) | 4.58 ± 0.54 | 4.77 ± 0.59 | 0.110 |
Insulin (pmol/L) | 88.2 ± 9.7 | 88.4 ± 9.7 | 0.975 |
HOMA-Index | 4.21 ± 0.47 | 4.13 ± 0.49 | 0.827 |
Office blood pressure | Â | Â | Â |
  Systolic (mmHg) | 132 ± 2.5 | 131 ± 2.0 | 0.437 |
  Diastolic (mmHg) | 80 ± 1.3 | 79 ± 1.3 | 0.269 |
Weight (kg) | 92.1 ± 2.6 | 92.4 ± 2.7 | 0.207 |
Body Mass Index (kg/m2) | 30.6 ± 0.8 | 30.7 ± 0.8 | 0.233 |
Lipids | Â | Â | Â |
  Total cholesterol (mmol/L) | 5.41 ± 0.1 | 5.21 ± 0.1 | 0.023 |
  LDL cholesterol (mmol/L) | 3.73 ± 0.1 | 3.55 ± 0.1 | 0.015 |
  HDL cholesterol (mmol/L) | 1.24 ± 0.04 | 1.17 ± 0.04 | < 0.001 |
  Triglycerides (mmol/L) | 1.89 ± 0.1 | 1.84 ± 0.1 | 0.602 |